GlassScriptPhysician profile
Douglas D Altchek
NPI 1366449340
$4,756.72
in general payments reported to CMS, 2019-2025
19 companies · $684 in 2025
The $684 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,781 · 2020: $406 · 2021: $249 · 2022: $646 · 2023: $434 · 2024: $557 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,580 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,579.71 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $735.37 | 2019-2023 | Olumiant, Taltz |
| Ucb, INC. | $573.76 | 2022-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $542.17 | 2019 | |
| Incyte Corporation | $505.05 | 2022-2024 | Opzelura |
| Pfizer INC. | $503.49 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $364.46 | 2019-2020 | |
| Janssen Biotech, INC. | $355.88 | 2019-2024 | Tremfya, Simponi Aria, Remicade |
| Allergan, INC. | $168.09 | 2019 | |
| Dermira, INC. | $156.76 | 2019-2021 | |
| Botanix Sb INC | $151.18 | 2025 | Sofdra |
| Novartis Pharmaceuticals Corporation | $131.62 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2019 | |
| Abbvie INC. | $121.38 | 2025 | |
| Novo Nordisk INC | $105.14 | 2020 | |
| Galderma Laboratories, L.P. | $87.03 | 2022-2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $52.70 | 2022 | |
| Amgen INC. | $32.01 | 2025 | Otezla |
| Regeneron Healthcare Solutions, INC. | $27.35 | 2025 | Libtayo |
| Dusa Pharmaceuticals, INC. | $18.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Altchek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.